Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004046 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy in Treating Women With Metastatic Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00004046 is a Phase 2 study of Breast Cancer that has completed, run by Daiichi Sankyo. The trial reports 1 study location across 1 state.
The verdict
NCT00004046, a Phase 2 study of Breast Cancer, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating women who have metastatic breast cancer that has not responded to previous therapy.
Conditions Studied
Interventions
- DRUG exatecan mesylate
Study Locations (1)
Texas
- University of Texas - MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-06 |
| Est. Completion | 2002-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004046
The ClinicalTrials.gov registry entry for NCT00004046 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which exatecan mesylate is the first listed.
NCT00004046 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00004046 about?
NCT00004046 is a clinical study titled "Chemotherapy in Treating Women With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating women who have metastatic breast cancer that has not responded to previous therapy.
What is the current status of trial NCT00004046?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-06. Estimated completion is 2002-04.
What conditions does trial NCT00004046 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00004046?
The interventions under investigation include: exatecan mesylate (DRUG).
Who is sponsoring clinical trial NCT00004046?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004046 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.